Immunological status does not influence hepatitis c virus or liver fibrosis in HIV-hepatitis C virus-coinfected

Julio Collazos1, José Antonio Cartón, Víctor Asensi

  • 1Infectious Disease Unit, Hospital de Galdácano-Usánsolo , Vizcaya, Spain.

Insights

In HIV-HCV-coinfected patients, immunological status did not impact Hepatitis C Virus (HCV) load or liver fibrosis progression. Alcohol abuse, HBsAg positivity, and platelet counts were key factors associated with liver fibrosis development.

Area of Science:

  • Hepatology
  • Immunology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) and Human Immunodeficiency Virus (HIV) coinfection is common.
  • The impact of immunological status on liver fibrosis and HCV viral load in coinfected patients remains unclear.

Purpose of the Study:

  • To investigate the association between immunological status and liver fibrosis and HCV viral load in HIV-HCV-coinfected patients.

Main Methods:

  • A cohort of HIV-HCV-coinfected patients was categorized into poor (CD4 ≤200/μl) or good (CD4 ≥500/μl) immunological status groups.
  • Liver fibrosis was assessed using transient elastometry and noninvasive indexes.
  • Multivariate analyses were performed to identify factors associated with liver fibrosis and HCV viral load.

Main Results:

  • Current or nadir CD4 counts were not associated with HCV viral load, liver fibrosis at evaluation, or fibrosis progression.
  • Alcohol abuse, HBsAg positivity, and lower platelet counts were independently associated with significant, advanced fibrosis, and cirrhosis.
  • Immunological status showed no association with any stage of liver fibrosis.

Conclusions:

  • Immunological status does not significantly influence HCV viral load or liver fibrosis development in HIV-HCV-coinfected patients.
  • Alcohol abuse, HBsAg positivity, and platelet count are crucial predictors of liver fibrosis in this population.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...